Compare Regeneron Pharmaceuticals Inc (REGN) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Valero Energy Corporation — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B), while Valero Energy Corporation trades at $391.21 (market cap $110.23B). The key difference: Valero Energy Corporation is the larger of the two by market cap, and Valero Energy Corporation pays the higher dividend (1.25%). Which is the better fit depends on your goals.
| REGN | VLO | |
|---|---|---|
Market Cap | $83.43B | $110.23B |
Sector | Health | Energy |
52-Week High | $852.03 | $388.95 |
52-Week Low | $555.51 | $156.39 |
Enterprise Value | $78.14B | $113.71B |
Dividend Yield | 0.46% | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Valero Energy (VLO) trades at $382.85, up 3.27% with strong technical momentum and bullish moving averages. The stock shows robust fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and attractive valuation ratios (P/E 15.97, P/S 0.83). Recent news highlights inclusion in growth stock lists and upcoming Q3 2026 earnings on October 22, 2026.
Outlook remains positive with favorable refining conditions and analyst consensus at Buy (58%). Key risks include revenue decline from $176.4B (2022) to $122.7B (2025) and political pressure on gas prices. The stock offers value but faces sector volatility and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
